How a big biotech’s start-up gamble went wrong
Behind the Money
Illumina's Cost-Cutting Plan
The biotech stock boom that was happening at the height of the pandemic starts to fizzle out. Illumina is getting caught up in litigation with regulators about Grail. The company began to face tough competition from a crop of early stage companies. And by the end of 2022, we had Illumina announcing a cost-cutting plan.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
